Results
|
|
1.
|
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). MedStar authors:
Year: 2017
Citation: - Journal of Clinical Oncology. 35(23):2647-2655, 2017 Aug 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Randomized Controlled Trial
All authors: - Asmar L, Blum JL, Brufsky AM, Colangelo LH, Dang CT, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Gomez HL, Hopkins JO, Jacobs SA, Jeong JH, Jones SE, Lyss AP, Mamounas EP, O'Shaughnessy JA, Paul D, Robert NJ, Swain SM, Vukelja SJ, Wolmark N, Yothers G
|
|
|
2.
|
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors:
Year: 2013
Citation: - Oncologist. 18(3):257-64, 2013.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM
|
|
|
3.
|
|
|
|
4.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors:
Year: 2014
Citation: - Annals of Oncology. 25(6):1116-21, 2014 Jun.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM
|
|
|
5.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
|
6.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
|
7.
|
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. MedStar authors:
Year: 2016
Citation: - Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Kidwell KM, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA, Zoon CK
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
|
|
11.
|
|
|
|
12.
|
|
|
|
13.
|
|
|
|
14.
|
|
|
|
15.
|
|
|
|
16.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Journal Article
- Randomized Controlled Trial
All authors: - Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G
|
|
|
17.
|
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). MedStar authors:
Year: 2024
Citation: - Journal of Clinical Oncology. 42(12):1344-1349, 2024 Apr 20.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gomez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N
|
|
|
18.
|
Reply to a. Avan et Al. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(15):1712, 2015 May 20.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Kiermaier A, Swain S
|
|
|
19.
|
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. MedStar authors:
Year: 2012
Citation: - Lancet. 379(9814):432-44, 2012 Feb 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Meta-Analysis
- Research Support, Non-U.S. Gov't
All authors: - Albain K, Bergh J, Clarke M, Cutter D, Darby S, Davies C, Di Leo A, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Godwin J, Gray R, McGale P, Pan HC, Peto R, Piccart M, Pritchard K, Swain S, Taylor C, Wang YC
|
|
|
20.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Allred DC, Anderson SJ, Costantino JP, Geyer CE Jr, Julian TB, Land SR, Mamounas EP, Nagtegaal ID, Paik S, Swain SM, Wickerham DL, Wolmark N
|
|
|
21.
|
Patient navigation significantly reduces delays in breast cancer diagnosis in the District of Columbia. MedStar authors:
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Alexander LM, Brem R, Caicedo L, Eng-Wong J, Frederick W, Funderburk W, Hoffman HJ, Huerta E, LaVerda NL, Levine PH, Patierno SR, Swain S, Young HA
|
|
|
22.
|
|
|
|
23.
|
|
|
|
24.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors:
Year: 2013
Citation: - Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL
|
|
|
25.
|
Reply to E.J. Moylan et al. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(6):606-7, 2014 Feb 20.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Geyer CE Jr, Swain SM, Tang G
|
|
|
26.
|
Treatment of HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(20):1964-5, 2015 May 14.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Baselga J, Clark E, Swain SM
|
|
|
27.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
|
|
28.
|
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. [Review] MedStar authors:
Year: 2021
Citation: - Cancers. 13(7), 2021 Mar 29.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Bottiglieri S, Carballido E, Cueto AD, Hicks JK, Imanirad I, Levine R, Nelson RS, Parker AS, Seligson ND, Swain SM, Tillman EM
|
|
|
29.
|
|
|
|
30.
|
|
|
|
31.
|
|
|
|
32.
|
|
|
|
33.
|
|
|
|
34.
|
|
|
|
35.
|
|
|
|
36.
|
|
|
|
37.
|
|
|
|
38.
|
|
|
|
39.
|
|
|
|
40.
|
|
|
|
41.
|
|
|
|
42.
|
|
|
|
43.
|
|
|
|
44.
|
|
|
|
45.
|
|
|
|
46.
|
|
|
|
47.
|
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. MedStar authors:
Year: 2022
Citation: - Cancers. 14(11), 2022 May 24.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Colomer R, Dadswell K, Dang C, de Haas SL, de la Cruz-Merino L, Delaloge S, Eiger D, Ewer MS, Ferrero JM, Restuccia E, Sarkar S, Swain SM, Verrill M, Werner TL
|
|
|
48.
|
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). MedStar authors:
Year: 2022
Citation: - Breast Cancer Research & Treatment. 2022 Mar 01
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Baez-Diaz L, Bandos H, Brufsky AM, Carolla RL, Fehrenbacher L, Geyer CE Jr, Hamm JT, Jacobs SA, Julian TB, Mamounas EP, Paterson AHG, Polikoff J, Provencher L, Rastogi P, Robidoux A, Swain SM, Ward PJ, Wolmark N
|
|
|
49.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors:
Year: 2013
Citation: - Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N
|
|
|
50.
|
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. MedStar authors:
Year: 2013
Citation: - Clinical Cancer Research. 19(13):3681-92, 2013 Jul 1.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Bais C, Brauer MJ, Chen D, Cheng JH, Chung AS, Clermont AC, Ferrara N, Haley B, Hegde P, James CD, Jubb A, Jurinka SS, Kaminker JS, Koeppen H, Kolumam G, Modrusan Z, Ozawa T, Phillips H, Scherer SJ, Schmidt M, Singh M, Stephan JP, Swain SM, Tam RN, Wu X, Yang SX, Yao J, Yeh RF, Yue P, Zhuang G
|
|
|
51.
|
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors:
Year: 2013
Citation: - Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J
|
|
|
52.
|
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Clark E, Cortes J, Im SA, Kiermaier A, Ross G, Swain SM
|
|
|
53.
|
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. MedStar authors:
Year: 2014
Citation: - BMC Cancer. 14:307, 2014.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Beattie M, Hurvitz S, Jahanzeb M, Kaufman PA, Lai C, Masaquel A, Mason G, O'Shaughnessy J, Rugo HS, Swain S, Tripathy D, Yoo B
|
|
|
54.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
55.
|
|
|
|
56.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
|
57.
|
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors:
Year: 2015
Citation: - Lancet Oncology. 16(9):1037-48, 2015 Sep.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
58.
|
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. MedStar authors:
Year: 2017
Citation: - JAMA Oncology. 3(3):335-341, 2017 Mar 01
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Bandos H, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Johnson NL, Kim SR, Lipchik C, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
|
|
59.
|
|
|
|
60.
|
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. MedStar authors:
Year: 2021
Citation: - Cancers. 13(9), 2021 May 08.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Aapro M, Abdel Aziz H, Abdel Karim K, Abulkhair O, Al-Sukhun S, Anderson BO, Aref AT, Arun B, Azim HA, Bahie Eldin N, Bakkach J, Balch CM, Conte P, El Saghir NS, El-Shinawi M, El-Zawahry HM, Elghazaly H, Elghazawy H, ElMahdy M, Foheidi M, Frolova M, Ghosn M, Giuliano AE, Gligorov J, Guarneri V, Gulluoglu BM, Kandil A, Leung JWT, Orecchia R, Paltuev RM, Penault-Llorca F, Perez EA, Poortmans P, Rugo HS, Sabry M, Shehata MA, Swain SM, Yang W, Yip CH
|
|
|
61.
|
|
|
|
62.
|
|
|
|
63.
|
|
|
|
64.
|
|
|
|
65.
|
|
|
|
66.
|
|
|
|
67.
|
|
|
|
68.
|
|
|
|
69.
|
|
|
|
70.
|
|
|
|
71.
|
|
|
|
72.
|
|
|
|
73.
|
|
|
|
74.
|
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. MedStar authors:
Year: 2022
Citation: - Cancers. 14(20), 2022 Oct 15.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Cortazar P, Cortes J, Dang C, du Toit Y, Gianni L, Heinzmann D, Hurvitz SA, Jackisch C, Knott A, Macharia H, Schneeweiss A, Slamon D, Song C, Swain SM, Valagussa P
|
|
|
75.
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(16):4233-4241, 2020 08 15.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Bandos H, Brauer HA, Geyer CE Jr, Goerlitz DS, Harris BT, Lucas PC, Mamounas EP, Rastogi P, Ren Y, Robidoux A, Swain SM, Tang G, Wolmark N
|
|
|
76.
|
|
|
|
77.
|
|
|
|
78.
|
|
|
|
79.
|
|
|
|
80.
|
|
|
|
81.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
82.
|
Twenty-five year results of the national cancer institute randomized breast conservation trial. MedStar authors:
Year: 2012
Citation: - Breast Cancer Research & Treatment. 132(1):197-203, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Camphausen K, Dan T, Danforth DN, Glatstein E, Lippman ME, Lita E, Sciuto L, Shih J, Simone NL, Smith SL, Swain SM
|
|
|
83.
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
Year: 2012
Citation: - New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
84.
|
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. MedStar authors:
Year: 2012
Citation: - Clinical Breast Cancer. 12(4):232-9, 2012 Aug.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Intramural
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Duong QN, Hewitt SM, Hoffman HJ, Levine PH, Portera CC, Swain SM, Takikita M, Yang SX
|
|
|
85.
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. MedStar authors:
Year: 2012
Citation: - Lancet Oncology. 13(7):734-42, 2012 Jul.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Anderson SJ, Baez-Diaz L, Brufsky AM, Costantino JP, Dakhil S, Falkson CI, Fehrenbacher L, Geyer CE Jr, Gralow JR, King KM, Lad T, Lembersky BC, Mamounas EP, Paterson AH, Perez EA, Robidoux A, Swain SM, Weir LM, Wolmark N, Zheng P
|
|
|
86.
|
|
|
|
87.
|
Drug discount program. MedStar authors:
Year: 2013
Citation: - JAMA. 310(15):1626-7, 2013 Oct 16.
Institution: - Washington Cancer Institute
Medline publication type:
|
|
|
88.
|
|
|
|
89.
|
|
|
|
90.
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
|
91.
|
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. MedStar authors:
Year: 2013
Citation: - Cancer Medicine. 2(2):178-84, 2013 Apr.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Intramural
All authors: - Ayed FB, Ayoub WB, Brown LM, Eissa S, Gail M, Kantor ED, Khalafallah S, Khaled H, Merajver S, Omar S, Schairer C, Soliman AS, Swain SM
|
|
|
92.
|
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [Review] MedStar authors:
Year: 2014
Citation: - Lancet. 384(9938):164-72, 2014 Jul 12.
Medline publication type:
- Journal Article
- Meta-Analysis
- Research Support, U.S. Gov't, P.H.S.
- Review
All authors: - Baselga J, Bergh J, Blohmer J, Blumenthal G, Bogaerts J, Bonnefoi H, Cameron D, Cortazar P, Costantino JP, Ditsch N, Eidtmann H, Eiermann W, Fasching PA, Gerber B, Geyer CE Jr, Gianni L, Justice R, Loibl S, Mamounas EP, Mehta K, Paik S, Pazdur R, Perou C, Piccart M, Prowell T, Rastogi P, Semiglazov V, Slaets L, Sridhara R, Swain SM, Tang S, Untch M, Valagussa P, von Minckwitz G, Wickerham DL, Wolmark N, Zhang L
|
|
|
93.
|
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors:
Year: 2015
Citation: - Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N
|
|
|
94.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA
|
|
|
95.
|
|
|
|
96.
|
|
|
|
97.
|
Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(18_suppl):LBA506, 2012 Jun 20
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky A, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE, Kuebler JP, Mamounas EP, Margolese RG, Paik S, Rastogi P, Shibata HR, Swain SM, Tang G, Wolmark N
|
|
|
98.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. MedStar authors:
Year: 2020
Citation: - Lancet Oncology. 21(4):519-530, 2020 Apr.
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Benyunes MC, Ciruelos E, Clark E, CLEOPATRA study group, Cortes J, Im SA, Im YH, Kim SB, Knott A, Loi S, Miles D, Monturus E, Restuccia E, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
99.
|
|
|
|
100.
|
|
